For immediate release |
12 May 2010 |
("Futura" or "the Company")
AGM Statement
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, will hold its Annual General Meeting in London later today.
At the meeting, Dr William Potter, the Company's Chairman, will make the following statement:
"The current financial year has started well across our business.
"The submission of the regulatory dossier for CSD500's marketing authorisation represents a major milestone for us and we continue to expect approval later this year. In addition, we have made good progress in our commercial negotiations on TPR100 and PET500 and look forward to updating the market on these negotiations in due course.
"We look forward to the future with excitement and with growing confidence."
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive |
Tel: +44 (0) 1483 685 670 |
|
|
mail to: james.barder@futuramedical.com |
|
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny |
Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan Communications |
|
Mark Court / Stasa Filiplic / George Prassas |
Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.